Dr. John Cush RheumNow
5 years 1 month ago
Scottish study of 78 000 veterans shows no association between military service and future OA knee/hip. 78K Vets compared to 253K non-Vets shows Vets with a lower risk of THR (HR 0.87), but not TKR (HR 1.02). https://t.co/JU7Q80qji1
Among a cohort of first-degree relatives of patients with rheumatoid arthritis (RA), certain patient characteristics, as well as symptoms, helped predict a possible increased risk for developing the disease, U.K. researchers reported.
Dr. John Cush RheumNow
5 years 1 month ago
Metanalysis of Colchicine in oronary artery disease (CAD) (13RCTs, n=13125), colchicine signif. reduces the risk of MI (OR 0.64) & CVA/TIA (OR 0.50), but has a higher rate of GI upset with no influence on all‐cause mortality (OR 0.96) https://t.co/CRDUFsc6lG
ATLANTA – The CDC's Advisory Committee on Immunization Practices today recommended that rheumatology patients being actively treated with high-dose corticosteroids, alkylating agents, antimetabolites, TNF blockers, and other biologic agents that are immunosuppressive or immunomodulatory receive a third dose of the Pfizer-BioNTech or Moderna mRNA COVID-19 vaccines.
Dr. John Cush RheumNow
5 years 1 month ago
Osteoarthritis vs. Rheumatoid Arthritis
https://t.co/qvVEcKqNAM https://t.co/WDyIZxoL7v
Dr. John Cush RheumNow
5 years 1 month ago
Watch Now:
The Sentinel Joint: Dr. Kathryn Dao ( @KDAO2011 ) reviews abstract POS0385 presented at the virtual EULAR 2021 meeting.
https://t.co/H3DcSHQWHr https://t.co/f7LDNz6oyL
Dr. John Cush RheumNow
5 years 1 month ago
Popular on RheumNow
https://t.co/BZsl8a6ArW
The U.S. Food and Drug Administration (FDA) has approved Octagam 10% [Immune Globulin Intravenous (Human)], as the first and only intravenous immunoglobulin (IVIg) formulation to be approved for adult dermatomyositis (DM). https://t.co/RNFsJadUZx
Dr. John Cush RheumNow
5 years 1 month ago
Popular post--
AstraZeneca announced that anifrolumab (Saphnelo or anifrolumab-fnia) was approved by the the FDA for that treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy.
https://t.co/22HVA32IAh https://t.co/CGkBW80un4
Dr. John Cush RheumNow
5 years 1 month ago
FDA has approved Xywav - gamma-hydroxybutyrate (GHB) for “idiopathic hypersomnia,” (people sleep 9+hrs/, yet never feel rested). GHB prev approved for narcolepsy https://t.co/38MBpmOAAA https://t.co/5pLLghCYtp
Dr. John Cush RheumNow
5 years 1 month ago
A Top Tweet this Week:
A large cohort study of rheumatoid arthritis (RA) patients shows that regular tea consumption was associated with a lower risk of RA.
https://t.co/ODTs7PdGTN https://t.co/69mi8IlBdj
Dr. John Cush RheumNow
5 years 1 month ago
In case you missed it…
TB rarely causes arthritis; accounts for 1-5% of all TB (10-30% of pulmonary TB) cases. May present as mono/oligoarthritis, tenosynovitis, dactylitis, Spondylitis (Potts disease), reactive arthritis (Poncets dz) or polyarthritis. https://t.co/RpMrRLQbEa
Dr. John Cush RheumNow
5 years 1 month ago
Dont make a point, make a difference - Seth Godin https://t.co/kJE3EGCY83
Dr. John Cush RheumNow
5 years 1 month ago
ICYMI: Can you manage FM without opioids? Study of 698 Fibromyalgia pts from a tertiary center finds 27.1% taking opioids. Opioid associated with longer Sx duration (>3 yrs), increased age, worse functional impairment & pain catastrophizing https://t.co/N1G4ZtkUE5
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.
In a head to head trial Upadacitinib was superior to Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis. 24wk DBRCT, 924 pts given either UPA 30/d vsDUP 300 EOW. ESI75 response@wk16, UPA 71% vs DUP 61% https://t.co/5cOoosKyao
